Aura Biosciences, INC 10-Q quarterly reports

Aura Biosciences reports increased R&D and G&A expenses in Q2 2026, announces a 20% workforce reduction to focus on ocular oncology, and highlights progress in bel-sar clinical trials.

Aura Biosciences reports increased R&D spend and net losses in Q3 2025, driven by clinical trial progression, while securing significant capital to extend its operational runway into H1 2027.

Aura Biosciences reports increased R&D spend and net losses in Q2 2025, fueled by progress in its lead oncology programs and a successful $69.9 million follow-on offering extending its cash runway into H1 2027.

Aura Biosciences reports a net loss of $27.5 million for Q1 2025, focusing on the development of bel-sar and expansion into new oncology indications.

Aura Biosciences, a clinical-stage biotech company, reported its third quarter 2024 financial results, highlighting progress in its bel-sar clinical trials and ongoing research and development efforts.

Aura Biosciences reports a net loss of $40 million for the first half of 2024, while advancing its bel-sar clinical programs.

Aura Biosciences reports a net loss of $19.7 million for the first quarter of 2024, while advancing its bel-sar clinical trials across multiple oncology indications.